Systemic lupus erythematosus (SLE) is characterized by diverse clinical and laboratory findings and multiple, frequently opposing cellular and cytokine aberrations. The T cell receptor (TCR) 6 chain is decreased in SLE T patients because of limited promoter activity, instability of an alternatively spliced TCR 6 mRNA missing crucial AU response elements and increased degradation by caspase 3. Its pace in the CD3 complex is taken by the FcR3 chain which signals through Syk. Lipid rafts form aggregates on the surface of T cells and together with the rewired TCR account for the aberrant signaling process in SLE T cells. In the lipid aggregates the adhesion molecule is present in increased amounts, which signal through ezrin. CD44 and phosphorylated ezrin positive cells are found in the kidneys of patients with lupus nephritis. It is hypothesized that altered cell surface membrane-mediated signaling in SLE T cells results in aberrant T cell function including inappropriate expression of adhesion molecules and homing to inflamed tissues. The objective of the proposed studies is to explore the role of TCR rewiring (FcR3 ->CD36) in effector SLE T cell function and establish the central role of Syk-mediated signaling in the expression of the SLE T cell phenotype and disease pathology. In addition, the contribution of cell membrane-mediated signaling in upregulating the expression of the adhesion molecule CD44 that results in inappropriate homing of T cells to the kidney will be studied. The proposed studies suggest the presence of molecular targets that can be modulated with gene transfer or drugs and have the potential to complement existing therapeutic modalities. In addition, they will identify several potential T cell based biomarkers. The long term goal of the ongoing and proposed research is the establishment of a """"""""molecular signature"""""""" for each patient, or subgroups of SLE patients that will help the diagnosis and personalized treatment.
Systemic lupus erythematosus afflicts more than one million Americans most of whom are women in the child bearing age. Current treatment is based primarily on indiscriminate immunosuppression. This application will explore the presence of molecular targets that can be modulated with gene transfer or drugs and have the potential to complement existing therapeutic modalities.
|Moulton, Vaishali R; Suarez-Fueyo, Abel; Meidan, Esra et al. (2017) Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends Mol Med 23:615-635|
|Comte, Denis; Karampetsou, Maria P; Yoshida, Nobuya et al. (2017) Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus. Arthritis Rheumatol 69:1035-1044|
|Zhou, Yi; Chen, Huimei; Liu, Li et al. (2017) CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice. J Immunol 198:2568-2577|
|Comte, Denis; Karampetsou, Maria P; Kis-Toth, Katalin et al. (2017) Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin-2. Arthritis Rheumatol 69:808-813|
|Nishi, Hiroshi; Furuhashi, Kazuhiro; Cullere, Xavier et al. (2017) Neutrophil Fc?RIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. J Clin Invest 127:3810-3826|
|Zhou, Yi; Chen, Huimei; Liu, Li et al. (2017) Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Faslpr Mice. J Immunol 198:1846-1854|
|Karampetsou, Maria P; Comte, Denis; Kis-Toth, Katalin et al. (2016) Decreased SAP Expression in T Cells from Patients with Systemic Lupus Erythematosus Contributes to Early Signaling Abnormalities and Reduced IL-2 Production. J Immunol 196:4915-24|
|Wang, Jianxun; Mizui, Masayuki; Zeng, Li-Fan et al. (2016) Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. J Clin Invest 126:2077-92|
|Volpi, Stefano; Santori, Elettra; Abernethy, Katrina et al. (2016) N-WASP is required for B-cell-mediated autoimmunity in Wiskott-Aldrich syndrome. Blood 127:216-20|
|Comte, Denis; Karampetsou, Maria P; Kis-Toth, Katalin et al. (2016) Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. Proc Natl Acad Sci U S A 113:9321-6|
Showing the most recent 10 out of 128 publications